Measuring Comorbidity in Cardiovascular Research: A Systematic Review

Background. Everything known about the roles, relationships, and repercussions of comorbidity in cardiovascular disease is shaped by how comorbidity is currently measured. Objectives. To critically examine how comorbidity is measured in randomized controlled trials or clinical trials and prospective...

Full description

Saved in:
Bibliographic Details
Main Authors: Harleah G. Buck, Jabar A. Akbar, Sarah Jingying Zhang, Janet A. Prvu Bettger
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Nursing Research and Practice
Online Access:http://dx.doi.org/10.1155/2013/563246
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850157634792980480
author Harleah G. Buck
Jabar A. Akbar
Sarah Jingying Zhang
Janet A. Prvu Bettger
author_facet Harleah G. Buck
Jabar A. Akbar
Sarah Jingying Zhang
Janet A. Prvu Bettger
author_sort Harleah G. Buck
collection DOAJ
description Background. Everything known about the roles, relationships, and repercussions of comorbidity in cardiovascular disease is shaped by how comorbidity is currently measured. Objectives. To critically examine how comorbidity is measured in randomized controlled trials or clinical trials and prospective observational studies in acute myocardial infarction (AMI), heart failure (HF), or stroke. Design. Systematic review of studies of hospitalized adults from MEDLINE CINAHL, PsychINFO, and ISI Web of Science Social Science databases. At least two reviewers screened and extracted all data. Results. From 1432 reviewed abstracts, 26 studies were included (AMI , HF , stroke ). Five studies used an instrument to measure comorbidity while the remaining used the presence or absence of an unsubstantiated list of individual diseases. Comorbidity data were obtained from 1–4 different sources with 35% of studies not reporting the source. A year-by-year analysis showed no changes in measurement. Conclusions. The measurement of comorbidity remains limited to a list of conditions without stated rationale or standards increasing the likelihood that the true impact is underestimated.
format Article
id doaj-art-2c2f3c331cfc467a9fcb41b1222a4940
institution OA Journals
issn 2090-1429
2090-1437
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Nursing Research and Practice
spelling doaj-art-2c2f3c331cfc467a9fcb41b1222a49402025-08-20T02:24:07ZengWileyNursing Research and Practice2090-14292090-14372013-01-01201310.1155/2013/563246563246Measuring Comorbidity in Cardiovascular Research: A Systematic ReviewHarleah G. Buck0Jabar A. Akbar1Sarah Jingying Zhang2Janet A. Prvu Bettger3School of Nursing, The Pennsylvania State University, 201 Health and Human Development East, University Park, PA 16802, USASchool of Nursing, Duke University, Duke University Medical Center 3322, 307 Trent Drive, Durham, NC 27710, USASchool of Nursing, Duke University, Duke University Medical Center 3322, 307 Trent Drive, Durham, NC 27710, USASchool of Nursing, Duke University, Duke University Medical Center 3322, 307 Trent Drive, Durham, NC 27710, USABackground. Everything known about the roles, relationships, and repercussions of comorbidity in cardiovascular disease is shaped by how comorbidity is currently measured. Objectives. To critically examine how comorbidity is measured in randomized controlled trials or clinical trials and prospective observational studies in acute myocardial infarction (AMI), heart failure (HF), or stroke. Design. Systematic review of studies of hospitalized adults from MEDLINE CINAHL, PsychINFO, and ISI Web of Science Social Science databases. At least two reviewers screened and extracted all data. Results. From 1432 reviewed abstracts, 26 studies were included (AMI , HF , stroke ). Five studies used an instrument to measure comorbidity while the remaining used the presence or absence of an unsubstantiated list of individual diseases. Comorbidity data were obtained from 1–4 different sources with 35% of studies not reporting the source. A year-by-year analysis showed no changes in measurement. Conclusions. The measurement of comorbidity remains limited to a list of conditions without stated rationale or standards increasing the likelihood that the true impact is underestimated.http://dx.doi.org/10.1155/2013/563246
spellingShingle Harleah G. Buck
Jabar A. Akbar
Sarah Jingying Zhang
Janet A. Prvu Bettger
Measuring Comorbidity in Cardiovascular Research: A Systematic Review
Nursing Research and Practice
title Measuring Comorbidity in Cardiovascular Research: A Systematic Review
title_full Measuring Comorbidity in Cardiovascular Research: A Systematic Review
title_fullStr Measuring Comorbidity in Cardiovascular Research: A Systematic Review
title_full_unstemmed Measuring Comorbidity in Cardiovascular Research: A Systematic Review
title_short Measuring Comorbidity in Cardiovascular Research: A Systematic Review
title_sort measuring comorbidity in cardiovascular research a systematic review
url http://dx.doi.org/10.1155/2013/563246
work_keys_str_mv AT harleahgbuck measuringcomorbidityincardiovascularresearchasystematicreview
AT jabaraakbar measuringcomorbidityincardiovascularresearchasystematicreview
AT sarahjingyingzhang measuringcomorbidityincardiovascularresearchasystematicreview
AT janetaprvubettger measuringcomorbidityincardiovascularresearchasystematicreview